Radiopharmacology

U.S. Department of Energy’s National Nuclear Security Administration Awards NorthStar Medical Radioisotopes $37 Million in Cooperative Agreement Funds to Further Domestic Molybdenum-99 (Mo-99) Production

Retrieved on:

Monday, August 30, 2021

Hospitals, Biotechnology, Energy, Nuclear, Radiology, Health, Pharmaceutical, Other Science, Science, Industry, Weapon, Company, Vesicoureteral reflux, University of Missouri Research Reactor Center, Isotopes of molybdenum, U.S. Department of Energy, Office of Inspector General, Pregnancy, Degenerative disease, LLC, University, Congress, Cancer, Nuclear medicine, Method, Physician, DOE, Uranium, System, Food, Doctor of Philosophy, NNSA, Child, Injection, USP, Cystography, Senior, U.S. Department of Defense Strategy for Operating in Cyberspace, Radiation exposure, Safety, Radiopharmacology, Nose, U.S. Navy Diving Manual, Risk, Patient, Technetium, Rash, Radiopharmaceutical, Radiation, Funding opportunity announcement, Sodium, FDA, Sodium pertechnetate, Allergy, Anaphylaxis, Water, Google Images, HEU, NorthStar, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Vaccine, Medical imaging, Birth control, Palladium, DOE/NNSA, the RadioGenix® System (Technetium Tc- 99m Generator), NorthStar Medical Radioisotopes, LLC (NorthStar), DOE/NNSA, THE RADIOGENIX® SYSTEM (TECHNETIUM TC- 99M GENERATOR), NORTHSTAR MEDICAL RADIOISOTOPES, LLC (NORTHSTAR)

NorthStar deeply appreciates these new cooperative agreement awards and this financial and technical support provided by DOE/NNSA, said Stephen Merrick, President and Chief Executive Officer.

Key Points:

NorthStar deeply appreciates these new cooperative agreement awards and this financial and technical support provided by DOE/NNSA, said Stephen Merrick, President and Chief Executive Officer.
We are proud to be the first and only company to achieve commercialized Mo-99 production through collaboration with DOE/NNSA to date.
We are working aggressively to ensure sustainable domestic Mo-99 supply through dual production and processing hubs for additional capacity and scheduling flexibility.
With inclusion of the current and past awards, NorthStar has been awarded a total of over $100 million in cooperative agreement funds by DOE/NNSA.

NorthStar Medical Radioisotopes and GE Healthcare Sign Exclusive U.S. Manufacturing and Distribution Agreement

Retrieved on:

Tuesday, August 3, 2021

Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Medicine, Health sciences, Radiopharmaceuticals, Physical sciences, Medical physics, Medicinal radiochemistry, Medicinal chemistry, Nuclear medicine, GE Healthcare, General Electric, Medical imaging, Radiopharmacology

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare today announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States.

Key Points:

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare today announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States.
This exclusive sales and manufacturing agreement marks NorthStars strong and growing relationship with GE Healthcare, and we look forward to working with the company in meeting the needs of radiopharmacy customers and the patients we all serve, said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT, ultrasound and nuclear medicine imaging.
GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE).

NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67) Exclusively to Clarity Pharmaceuticals for Its Targeted Copper Theranostics Programs

Retrieved on:

Tuesday, May 25, 2021

Under the agreement, NorthStar will supply Cu-67 exclusively to Clarity Pharmaceuticals as an active pharmaceutical ingredient used to support Claritys Targeted Copper Theranostics (TCT) programs.

Key Points:

Under the agreement, NorthStar will supply Cu-67 exclusively to Clarity Pharmaceuticals as an active pharmaceutical ingredient used to support Claritys Targeted Copper Theranostics (TCT) programs.
Previously, the lack of an effective copper chelating technology has limited the clinical development of Cu-67 products and subsequent commercial production of Cu-67, said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
NorthStar is addressing the need for reliable Cu-67 radioisotope supply by advancing towards commercial-scale production.
Clarity leads the world in the development and commercialization of TCT, said Alan Taylor, PhD, Executive Chairman of Clarity Pharmaceuticals.

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery

Retrieved on:

Monday, May 24, 2021

Physical sciences, Chemistry, Chemical elements, Radiopharmaceuticals, Medicinal radiochemistry, Medicinal chemistry, Chlorides, Radiation therapy, Radiopharmacology, Actinium(III) iodide, Actinium(III) chloride, Provisional application

WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation.

Key Points:

WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation.
Radiopharmaceutical therapy is a promising approach to treat cancer and other diseases using radioactive metals bound with proteins/antibodies to target and kill cells.
If validated through further evaluation, it could potentially improve efficacy and safety and enhance manufacturing efficiency of Actinium-based radiopharmaceuticals.
Monopar and NorthStar plan to explore both internal development and out-licensing opportunities of this promising approach in Actinium-based radiopharmaceuticals.

NorthStar Medical Radioisotopes to Present at the Emerging Medtech Summit 2021

Retrieved on:

Tuesday, May 4, 2021

Oncology, Health, Medical devices, Radiology, Pharmaceutical, Cardiology, Biotechnology, Health sciences, Medicine, Radiopharmaceuticals, Physical sciences, Medicinal radiochemistry, Medicinal chemistry, Radiation therapy, Radiobiology, Radiopharmacology, Northstar, Medtech

b'NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present a corporate overview at the Emerging Medtech Summit 2021, on May 12, 2021 at 3:57 p.m. PT in Dana Point, Ca.

Key Points:

b'NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present a corporate overview at the Emerging Medtech Summit 2021, on May 12, 2021 at 3:57 p.m. PT in Dana Point, Ca.
The Emerging Medtech Summit 2021 brings together top strategists, investors and innovators driving the future of healthcare.
Information about the Summit is available here .\nStephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will provide an update on NorthStar, including its progress in advancing U.S. radioisotope production and its expanding portfolio.
Therapeutic radioisotopes are increasingly important cancer treatment options, and NorthStar is developing commercial-scale production technologies to meet high demand for their use in ongoing clinical trials by multiple pharmaceutical companies.

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Retrieved on:

Tuesday, April 13, 2021

Oncology, Medical devices, Health, Radiology, Cardiology, Biotechnology, Physical sciences, Natural sciences, Chemistry, Radiopharmaceuticals, Medicinal radiochemistry, Radioactivity, Radiobiology, Medicinal chemistry, Technetium-99m, Radiopharmacology, Isotopes of molybdenum, Northstar

b'NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.\nThis press release features multimedia.

Key Points:

b'NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.\nThis press release features multimedia.
The new structure enables NorthStar to advance its radioisotope development and commercialization planning efforts in parallel with ongoing expansion programs for increased U.S. Mo-99 capacity and production.
The facility will enable NorthStar to more than double its production of Mo-99, used with RadioGenix Systems to produce Tc-99m.
Like other NorthStar processes, accelerator production of Mo-99 using the \xe2\x80\x9cneutron knock-out\xe2\x80\x9d method is non-uranium based and highly efficient.

Isotopia Molecular Imaging and Molecular Targeting Technologies have signed a clinical supply agreement for Lu177 n.c.a.

Retrieved on:

Thursday, March 25, 2021

Physical sciences, Medicine, Health sciences, Radiopharmaceuticals, Medicinal radiochemistry, Medicinal chemistry, Radiobiology, Medical physics, Molecular imaging, Radiopharmacology, Radiation therapy

PETACH TIKVA, Israel, March 25, 2021 /PRNewswire/ --Isotopia Molecular Imaging is pleased to announce that it has begun a collaboration with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biopharmaceutical company, for the supply of the medical radioisotope no-carrier-added 177Lu(n.c.a.

Key Points:

PETACH TIKVA, Israel, March 25, 2021 /PRNewswire/ --Isotopia Molecular Imaging is pleased to announce that it has begun a collaboration with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biopharmaceutical company, for the supply of the medical radioisotope no-carrier-added 177Lu(n.c.a.
Molecular Targeting Technologies, Inc. (West Chester, PA, USA)is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers.
Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and Israeli's leading scientists in the field of radiopharmaceuticals.
Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals

Retrieved on:

Wednesday, March 3, 2021

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business.

Key Points:

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business.
View the full release here: https://www.businesswire.com/news/home/20210303005055/en/
Dave Wilson, RPh., BCNP, VP Advanced Radiopharmaceutical and Therapeutic Technologies, NorthStar Medical Radioisotopes (Photo: Business Wire)
In conjunction with other organizational changes, NorthStar has appointed Dave Wilson, RPh., BCNP, as Vice President, Advanced Radiopharmaceutical and Therapeutic Technologies.
NorthStar is also actively developing and growing its strategic portfolio of specialized SPECT radiopharmaceuticals to meet increasing clinical needs for SPECT imaging, driven by scientific advancements in cardiology and oncology.
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that develops, produces and manufactures reliable and environmentally-friendly diagnostic and therapeutic radiopharmaceuticals.

NorthStar Medical Radioisotopes to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on:

Tuesday, March 2, 2021

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 10, 2021.

Key Points:

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 10, 2021.
We are excited to share information about NorthStars success in advancing our commercialized product and expansion initiatives for reliable medical radioisotope production with the investor community at the H.C. Wainwright Global Life Sciences Conference, said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
NorthStar continues to further deploy its innovative technology and development expertise to meet growing demands for medical radioisotopes.
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that develops, produces and manufactures reliable and environmentally-friendly diagnostic and therapeutic radiopharmaceuticals.

Bruce Power and IsoGen set first critical milestone for exclusive irradiation service provided to ITM for its production of no-carrier-added Lutetium-177

Retrieved on:

Tuesday, September 29, 2020

Thereby a dedicated mock-up of the isotope production system was developed for validation, testing and training which will start in fall 2020.

Key Points:

Thereby a dedicated mock-up of the isotope production system was developed for validation, testing and training which will start in fall 2020.
The medical radioisotope Lutetium-177 (177Lu) will be obtained by irradiating Ytterbium-176 at the Bruce Power Reactors, as contractually stipulated in an exclusive agreement between Bruce Power, IsoGen and ITM Medical Isotopes GmbH.
Bruce Power Reactors are uniquely positioned to fulfil the necessary requirements to reach ITMs high standards validated in a successful feasibility study September last year.
The construction of the isotope production system at Bruce Power by IsoGen is currently planned to start in January 2021 once the mock-up has been fully tested.